Fig. 6: Fenofibrate delays the onset of age-related disorders in humans.
a, Outline of the studies. Serum was collected from young mice (3 months old, male) and aged mice (21 months old, male) and subjected to metabolomics analysis. b, Differential abundance score shows the changes of metabolites in serum from young and aged mice. The red horizontal line represents the differential enrichment of PPAR signaling pathway in serum from young and aged mice; the red asterisks represent the statistical difference (P < 0.001). c, Protein levels of PPARα after overexpression of miRNA-378a in primary hepatocytes (n = 3 biological replicates) (upper left) or miRNA-191 in BMSCs (n = 6 biological replicates) (bottom left), and their quantitative analysis (right). d, Outline of the studies. e, Cumulative incidence of type 2 diabetes, major osteoporotic fracture, dementia and all-cause mortality in participants initiating fenofibrate and those using simvastatin. f, Life expectancy. Data are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001, as determined by two-tailed t-test. mo, months.
